Aclaris Therapeutics Inc (ACRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) has a cash flow conversion efficiency ratio of -0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.93 Million) by net assets ($120.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aclaris Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Aclaris Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Aclaris Therapeutics Inc (ACRS) total liabilities for a breakdown of total debt and financial obligations.
Aclaris Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aclaris Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alcor Micro
TWO:8054
|
-0.035x |
|
Beijing Hanjian Heshan Pipeline Co Ltd
SHG:603616
|
-0.093x |
|
Huaiji Dengyun Auto-parts Holding Co Ltd
SHE:002715
|
0.036x |
|
Ningbo United Group Co Ltd
SHG:600051
|
0.022x |
|
Ferm. Casino Mun. Canne
PA:FCMC
|
0.020x |
|
Altimmune Inc
NASDAQ:ALT
|
-0.086x |
|
NUIX Ltd
AU:NXL
|
0.069x |
|
NEL ASA ADR/30 NK -20
F:D7GA
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Aclaris Therapeutics Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Aclaris Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $155.55 Million | $-20.07 Million | -0.129x | +74.10% |
| 2023-12-31 | $157.18 Million | $-78.33 Million | -0.498x | -45.75% |
| 2022-12-31 | $197.62 Million | $-67.57 Million | -0.342x | -29.42% |
| 2021-12-31 | $197.34 Million | $-52.13 Million | -0.264x | +74.25% |
| 2020-12-31 | $37.65 Million | $-38.63 Million | -1.026x | +25.62% |
| 2019-12-31 | $69.91 Million | $-96.44 Million | -1.380x | -194.38% |
| 2018-12-31 | $215.12 Million | $-100.81 Million | -0.469x | -93.11% |
| 2017-12-31 | $225.26 Million | $-54.66 Million | -0.243x | -18.86% |
| 2016-12-31 | $169.49 Million | $-34.60 Million | -0.204x | +7.27% |
| 2015-12-31 | $92.52 Million | $-20.37 Million | -0.220x | -159.84% |
| 2014-12-31 | $-20.75 Million | $-7.64 Million | 0.368x | -31.48% |
| 2013-12-31 | $-9.16 Million | $-4.92 Million | 0.537x | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more